Nippon Shokubai has concluded a licence agreement with its Japanese compatriot and affiliate company, Rena Therapeutics, to make and sell heteroduplex oligonucleotide (HDO) as a research reagent to industry and academia in all countries where it is covered by patents. Rena has existing licences with Ionis Pharmaceuticals and Takeda Pharmaceutical.
Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production planning of superabsorbent polymers (SAPs) based on acrylic acid, and has started operations at its plant in Himeji following all the necessary validations and modifications. This is in line with its ‘TechnoAmenity for the future’ strategy, which was unveiled in April 2021 and will be extended to other products.
Japan’s Nippon Shokubai has decided to begin facility design for a new plant to make its Ionel brand of lithium bis(fluorosulfonyl) imide (LiFSI) electrolytes for lithium-ion batteries. The plant, at the site of the Nisshoku Techno Fine Chemical subsidiary, will have 2,000 tonnes/year of capacity. Construction will begin by the spring of 2023.